S

Soligenix
D

SNGX

1.81000
USD
-0.02
(-1.09%)
مغلق
حجم التداول
227
الربح لكل سهم
-3
العائد الربحي
-
P/E
-1
حجم السوق
5,908,466
أصول ذات صلة
A
ALT
-0.05500
(-0.95%)
5.71000 USD
B
BLRX
-0.26000
(-6.67%)
3.64000 USD
C
CVM
0.10000
(4.10%)
2.54000 USD
C
CYCC
-0.01000
(-0.69%)
1.44000 USD
S
SGMO
-0.02030
(-4.11%)
0.47370 USD
V
VSTM
0.83500
(11.16%)
8.31500 USD
المزيد
الأخبار المقالات

العنوان: Soligenix Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).